Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of Replimune Group in a report issued on Tuesday, November 12th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.73) per share for the quarter, up from their previous estimate of ($0.79). HC Wainwright has a "Buy" rating and a $17.00 price target on the stock. The consensus estimate for Replimune Group's current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Replimune Group's Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.
REPL has been the topic of several other reports. Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a "buy" rating and a $17.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Replimune Group presently has an average rating of "Buy" and an average price target of $16.80.
Get Our Latest Report on REPL
Replimune Group Stock Performance
NASDAQ REPL traded down $0.63 on Friday, hitting $10.77. 336,307 shares of the stock were exchanged, compared to its average volume of 1,032,731. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. The business's fifty day moving average is $11.44 and its 200 day moving average is $9.50. Replimune Group has a 52 week low of $4.92 and a 52 week high of $12.97. The company has a market capitalization of $736.88 million, a PE ratio of -3.74 and a beta of 1.19.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Parkman Healthcare Partners LLC raised its holdings in Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock worth $8,371,000 after purchasing an additional 238,747 shares during the last quarter. Arizona PSPRS Trust bought a new position in shares of Replimune Group during the 3rd quarter worth about $834,000. Baker BROS. Advisors LP boosted its position in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Replimune Group during the 3rd quarter worth about $133,000. Finally, Braidwell LP lifted its position in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. Institutional investors own 92.53% of the company's stock.
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
